Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells

Cancer Letters

Volumn 340, Issue 1, 2013, Pages 113-123

  Lu, Yuhua ^a,b   Zhu, Hui ^a   Shan, Haiyan ^a   Lu, Junjie ^a   Chang, Xu ^a   Li, Xiaohong ^a   Lu, Jingjing ^a   Fan, Xiangjun ^a   Zhu, Shajun ^a   Wang, Yao ^a   Guo, Qingsong ^a   Wang, Lei ^a   Huang, Yan ^a   Zhu, Mingyan ^a   Wang, Zhiwei ^a  

^a NANTONG UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Nanog; Oct4; Pancreatic cancer

Indexed keywords

CASPASE 3; CHEMOKINE RECEPTOR CXCR4; GELATINASE A; GELATINASE B; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN BCL 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR NANOG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CXCR4 GENE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; METASTASIS POTENTIAL; MMP2 GENE; MMP9 GENE; MOUSE; NANOG GENE; NONHUMAN; OCT4 GENE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; SURVIVAL RATE; TIMP1 GENE; TUMOR INVASION; UPREGULATION;

CANCER STEM CELLS; NANOG; OCT4; PANCREATIC CANCER;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PANCREATIC NEOPLASMS; RNA INTERFERENCE; TUMOR BURDEN;

EID: 84883828891     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.009     Document Type: Article

References (61)

1. Bao B., Ali S., Ahmad A., Azmi A.S., Li Y., Banerjee S., Kong D., Sethi S., Aboukameel A., Padhye S.B., Sarkar F.H. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PloS one 2012, 7:e50165.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. Ca-Cancer J. Clin. 2013, 63(2013):11-30.
3. Shi S., Yao W., Xu J., Long J., Liu C., Yu X. Combinational therapy: new hope for pancreatic cancer?. Cancer Lett. 2012, 317:127-135.
4. Zhou B., Wu Q., Chen G., Zhang T.P., Zhao Y.P. NOP14 promotes proliferation and metastasis of pancreatic cancer cells. Cancer Lett. 2012, 322:195-203.
5. Gaviraghi M., Tunici P., Valensin S., Rossi M., Giordano C., Magnoni L., Dandrea M., Montagna L., Ritelli R., Scarpa A., Bakker A. Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci. Rep. 2011, 31:45-55.
6. Ni X., Yang J., Li M. Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. Cancer Lett. 2012, 324:179-185.
7. Adikrisna R., Tanaka S., Muramatsu S., Aihara A., Ban D., Ochiai T., Irie T., Kudo A., Nakamura N., Yamaoka S., Arii S. Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology 2012, 143:U234-U448.
8. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., Yan P.S., Huang T.H.M., Nephew K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68:4311-4320.
9. Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan Q., Jordan S., Duncan L.M., Weishaupt C., Fuhlbrigge R.C., Kupper T.S., Sayegh M.H., Frank M.H. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
10. Marotta L.L., Polyak K. Cancer stem cells: a model in the making. Curr. Opin. Genet. Dev. 2009, 19:44-50.
11. Kusumbe A.P., Bapat S.A. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009, 69:9245-9253.
12. Jordan C.T., Guzman M.L., Noble M. Mechanisms of disease - cancer stem cells. New Engl. J. Med. 2006, 355:1253-1261.
13. Li C.W., Heidt D.G., Dalerba P., Burant C.F., Zhang L.J., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
14. Bednar F., Simeone D.M. Pancreatic cancer stem cells and relevance to cancer treatments. J. Cell Biochem. 2009, 107:40-45.
15. Dorado J., Lonardo E., Miranda-Lorenzo I., Heeschen C. Pancreatic cancer stem cells: new insights and perspectives. J. Gastroenterol. 2011, 46:966-973.
16. Li Y., Kong D., Ahmad A., Bao B., Sarkar F.H. Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett. 2013, 340:94-100.
17. Wei H.J., Yin T., Zhu Z., Shi P.F., Tian Y., Wang C.Y. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment. Hepatobiliary Pancreatic Dis. Int.: HBPD. INT 2011, 10:428-434.
18. Wang X., Zhao Y., Xiao Z., Chen B., Wei Z., Wang B., Zhang J., Han J., Gao Y., Li L., Zhao H., Zhao W., Lin H., Dai J. Alternative translation of OCT4 by an internal ribosome entry site and its novel function in stress response. Stem Cells (Dayton, Ohio) 2009, 27:1265-1275.
19. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Gen. 2008, 40:499-507.
20. Feske S. Calcium signalling in lymphocyte activation and disease. Nat. Rev. Immunol. 2007, 7:690-702.
21. Darini C.Y., Pisani D.F., Hofman P., Pedeutour F., Sudaka I., Chomienne C., Dani C., Ladoux A. Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential. Oncogene 2012, 31:2438-2449.
22. Noh K.H., Kim B.W., Song K.H., Cho H., Lee Y.H., Kim J.H., Chung J.Y., Kim J.H., Hewitt S.M., Seong S.Y., Mao C.P., Wu T.C., Kim T.W. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J. Clin. Invest. 2012, 122:4077-4093.
23. Huang P., Chen J., Wang L., Na Y.Q., Kaku H., Ueki H., Sasaki K., Yamaguchi K., Zhang K., Saika T., Nasu Y., Watanabe M., Kumon H. Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence. Med. Oncol. 2012, 29:829-834.
24. Jeter C.R., Liu B., Liu X., Chen X., Liu C., Calhoun-Davis T., Repass J., Zaehres H., Shen J.J., Tang D.G. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011, 30:3833-3845.
25. Mak V.C.Y., Siu M.K.Y., Wong O.G.W., Chan K.K.L., Ngan H.Y.S., Cheung A.N.Y. Dysregulated stemness-related genes in gynecological malignancies. Histol. Histopathol. 2012, 27:1121-1130.
26. Zhou Z.C., Dong Q.G., Fu D.L., Gong Y.Y., Ni Q.X. Characteristics of Notch2 pancreatic cancer stem-like cells and the relationship with centroacinar cells. Cell Biol. Int. 2013, 10.1002/cbin.10102.
27. Wen J., Park J.Y., Park K.H., Chung H.W., Bang S., Park S.W., Song S.Y. Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis. Pancreas 2010, 39:622-626.
28. Amsterdam A., Raanan C., Schreiber L., Polin N., Givol D. LGR5 and Nanog identify stem cell signature of pancreas beta cells which initiate pancreatic cancer. Biochem. Biophys. Res. Commun. 2013, 433:157-162.
29. Chiou S.H., Wang M.L., Chou Y.T., Chen C.J., Hong C.F., Hsieh W.J., Chang H.T., Chen Y.S., Lin T.W., Hsu H.S., Wu C.W. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010, 70:10433-10444.
30. Wong D.J., Liu H., Ridky T.W., Cassarino D., Segal E., Chang H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2:333-344.
31. Boiani M., Scholer H.R. Regulatory networks in embryo-derived pluripotent stem cells. Nat. Rev. Mol. Cell Biol. 2005, 6:872-884.
32. Chavez L., Bais A.S., Vingron M., Lehrach H., Adjaye J., Herwig R. In silico identification of a core regulatory network of OCT4 in human embryonic stem cells using an integrated approach. BMC Genomics 2009, 10:314.
33. Wei H.J., Yin T., Zhu Z., Shi P.F., Tian Y., Wang C.Y. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment. Hepatob. Pancreat. Dis. 2011, 10:428-434.
34. Chiou S.H., Yu C.C., Huang C.Y., Lin S.C., Liu C.J., Tsai T.H., Chou S.H., Chien C.S., Ku H.H., Lo J.F. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin. Cancer Res. 2008, 14:4085-4095.
35. Ezeh U.I., Turek P.J., Reijo R.A., Clark A.T. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer-Am. Cancer Soc. 2005, 104:2255-2265.
36. Ghosh D., Qin Z.S. Statistical Issues in the Analysis of ChIP-Seq and RNA-Seq Data. Genes 2010, 1:317-334.
37. Rodda D.J., Chew J.L., Lim L.H., Loh Y.H., Wang B., Ng H.H., Robson P. Transcriptional regulation of nanog by OCT4 and SOX2. J. Biol. Chem. 2005, 280:24731-24737.
38. Kuroda T., Tada M., Kubota H., Kimura H., Hatano S.Y., Suemori H., Nakatsuji N., Tada T. Octamer and sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol. Cell. Biol. 2005, 25:2475-2485.
39. Chiba T., Zheng Y.W., Kita K., Yokosuka O., Saisho H., Onodera M., Miyoshi H., Nakano M., Zen Y., Nakanuma Y., Nakauchi H., Iwama A., Taniguchi H. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007, 133:937-950.
40. Tang S.N., Fu J., Nall D., Rodova M., Shankar S., Srivastava R.K. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics, International journal of cancer. J. Int. du. Cancer 2012, 131:30-40.
41. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
42. Acloque H., Adams M.S., Fishwick K., Bronner-Fraser M., Nieto M.A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 2009, 119:1438-1449.
43. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 2009, 119:1417-1419.
44. Kucia M., Jankowski K., Reca R., Wysoczynski M., Bandura L., Allendorf D.J., Zhang J., Ratajczak J., Ratajczak M.Z. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J. Mol. Histol. 2004, 35:233-245.
45. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
46. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
47. Han H., Bourboulia D., Jensen-Taubman S., Isaac B., Wei B., Stetler-Stevenson W.G. An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells. Oncogene 2013, 10.1038/onc.2013.61.
48. Robey R.W., Polgar O., Deeken J., To K.W., Bates S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007, 26:39-57.
49. Yun S.M., Jung K.H., Lee H., Son M.K., Seo J.H., Yan H.H., Park B.H., Hong S., Hong S.S. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Lett. 2013, 331:250-261.
50. Verma G., Bhatia H., Datta M. Gene expression profiling and pathway analysis identify the integrin signaling pathway to be altered by IL-1beta in human pancreatic cancer cells: role of JNK. Cancer Lett. 2012, 320:86-95.
51. Bao B., Wang Z., Ali S., Kong D., Li Y., Ahmad A., Banerjee S., Azmi A.S., Miele L., Sarkar F.H. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011, 307:26-36.
52. Brabletz S., Bajdak K., Meidhof S., Burk U., Niedermann G., Firat E., Wellner U., Dimmler A., Faller G., Schubert J., Brabletz T. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011, 30:770-782.
53. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
54. Collins M.A., Bednar F., Zhang Y., Brisset J.-C., Brisset J.-C., Galb C.J., Rakshit S., Flannagan K.S., Adsay N.V., Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 2012, 122:639-653.
55. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
56. Tian H., Callahan C.A., DuPree K.J., Darbonne W.C., Ahn C.P., Scales S.J., de Sauvage F.J. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl. Acad. Sci. USA 2009, 106:4254-4259.
57. An Y., Cai B., Chen J., Lv N., Yao J., Xue X., Tu M., Tang D., Wei J., Jiang K., Wu J., Li Q., Gao W., Miao Y. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Cancer Lett. 2013, 329:228-235.
58. Li C., Wu J.J., Hynes M., Dosch J., Sarkar B., Welling T.H., Pasca di Magliano M., Simeone D.M. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011, 141:2218-2227. e5.
59. Joo K.M., Jin J., Kim E., Ho Kim K., Kim Y., Gu Kang B., Kang Y.J., Lathia J.D., Cheong K.H., Song P.H., Kim H., Seol H.J., Kong D.S., Lee J.I., Rich J.N., Lee J., Nam D.H. MET signaling regulates glioblastoma stem cells. Cancer Res. 2012, 72:3828-3838.
60. Li Y., Li A., Glas M., Lal B., Ying M., Sang Y., Xia S., Trageser D., Guerrero-Cazares H., Eberhart C.G., Quinones-Hinojosa A., Scheffler B., Laterra J. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc. Natl. Acad. Sci. USA 2011, 108:9951-9956.
61. De Bacco F., Luraghi P., Medico E., Reato G., Girolami F., Perera T., Gabriele P., Comoglio P.M., Boccaccio C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl. Cancer Inst. 2011, 103:645-661.